- Home
- NEGG vs ADCT Comparison
NEGG vs ADCT Comparison
Compare NEGG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | ADCT |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | Switzerland |
| Employees | 762 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.1M | 484.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NEGG | ADCT |
|---|---|---|
| Price | $40.26 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 31.6K | ★ 903.2K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | $1.15 |
| Revenue Next Year | N/A | $86.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $0.21 | $1.05 |
| 52 Week High | $137.84 | $4.98 |
Technical Indicators
Market Signals| Indicator | NEGG | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 48.68 |
| Support Level | $29.87 | $3.79 |
| Resistance Level | $56.73 | $4.63 |
| Average True Range (ATR) | 3.05 | 0.31 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 2.43 | 17.79 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).